Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial

The Lancet

Volumn 375, Issue 9708, 2010, Pages 49-55

  Vajo, Zoltan ^b   Tamas, Ferenc ^c   Sinka, Laszlo ^c   Jankovics, Istvan ^a  

^a NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c State Primary Care Centre   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM PHOSPHATE; FLUVAL AB; FLUVAL P; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMAGGLUTINATION; HUMAN; HUNGARY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; PANDEMIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; SWELTERING; UNSPECIFIED SIDE EFFECT; VIRUS STRAIN;

EID: 73149120237     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62039-0     Document Type: Article

References (25)

1. Ginsberg M., Hopkins J., Maroufi A., et al. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 58 (2009) 400-402
2. WHO. DG statement following the meeting of the Emergency Committee (June, 2009). http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html (accessed Sept 29, 2009).
3. WHO. Pandemic (H1N1) (2009-update 67). http://www.who.int/csr/don/2009_09_25/en/index.html (accessed Sept 29, 2009).
4. Vajo Z., Kosa L., Visontay I., Jankovics M., and Jankovics I. Inactivated whole virus influenza A (H5N1) vaccine. Emerg Infect Dis 13 (2007) 807-808
5. Fazekas G., Martosne-Mendi R., Jankovics I., Szilvasy I., and Vajo Z. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin Vaccine Immunol 16 (2009) 437-443
6. Vajo Z., Kosa L., Szilvasy I., et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J 27 (2008) 1052-1056
7. Vajo Z., Kósa, L, Szilvásy I., et al. Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval-a useful approach to pandemic vaccine development even in less well developed countries?. Influenza Other Respir Viruses 2 (2008) 211-218
8. WHO. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development (June, 2009). http://www.who.int/csr/resources/publications/swineflu/ivr153_20090608_e n.pdf (accessed Oct 9, 2009).
9. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5 (1977) 237-247
10. European Directoriate for the Quality Medicines. European Pharmacopia, 5.8 CD, 7/2007. Strasbourg: European Directoriate for the Quality Medicines (2007) 3406-3407
11. European Medicines Agency. EU recommendations for the seasonal influenza vaccine composition for the season 2009/2010. Document reference: EMEA/CHMP/BWP/133895/2009/Rev 1. London: European Directoriate for the Quality Medicines (2009). http://www.emea.europa.eu/pdfs/human/bwp/13389509en.pdf (accessed Sept 29, 2009).
12. Klimov A., and Cox N. Serologic diagnosis of influenza virus infections by hemagglutination inhibition. Influenza Laboratory Course (2003), Centres for Disease Control, Atlanta
13. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, March, 1997 (CPMP/BWP/214/96) (1997), European Agency for the Evaluation of Medicinal Products, London
14. European Centre for Disease Prevention and Control. Technical report. Expert advisory groups on human H5N1 vaccines. Scientific questions. European Centre for Disease Prevention and Control, Stockholm, Sweden (March, 2007). http://www.ecdc.europa.eu/en/publications/Publications/0708_TER_Expert_A dvisory_Groups_on_Human_H5N1_Vaccines_Scientific_Questions.pdf (accessed Sept 29, 2009).
15. US Food and Drug Administration. Draft guidance on clinical data needed to support the licensure of pandemic influenza vaccines (May, 2007). http://www.fda.gov/cber/gdlns/panfluvac.htm (accessed Sept 30, 2009).
16. Leroux-Roels I., Borkowski A., Vanwolleghem T., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
17. Ehrlich H.J., Müller M., Oh H.M., et al., for the Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 (2008) 2573-2584
18. Nolan T.M., Richmond P.C., Skeljo M.V., et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26 (2008) 4160-4167
19. Vajo Z. Influenza A (H5N1) pandemic prototype vaccine Fluval. Expert Rev Vaccines 8 (2009) 619-624
20. Greenberg M.E., Lai M.H., Hartel G.F., et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine-preliminary report. N Engl J Med (2009) 10.1056/NEJMoa0907413 published online Sept 10.
21. Clark T.W., Pareek M., Hoschler K., et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine-preliminary report. N Engl J Med (2009) 10.1056/NEJMoa0907650 published online Sept 10.
22. Voordouw A.C., Sturkenboom M.C., Dieleman J.P., et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 292 (2004) 2089-2095
23. Dennis C. Flu-vaccine makers toil to boost supply. Nature 440 (2006) 1099
24. Profeta M.L., Bigatello A., Vacchini V., Bramati L., and Ferrante P. Comparison between killed subunit influenza vaccines and whole virion preparations: study of reactions and protective efficacy in children and adults. Boll Ist Sieroter Milan 58 (1980) 457-474
25. Katz J., Hancock K., Veguilla V., et al. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58 (2009) 521-524